These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 16186281)

  • 1. Glycated and oxidized protein degradation products are indicators of fasting and postprandial hyperglycemia in diabetes.
    Ahmed N; Babaei-Jadidi R; Howell SK; Thornalley PJ; Beisswenger PJ
    Diabetes Care; 2005 Oct; 28(10):2465-71. PubMed ID: 16186281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. alpha-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia.
    Beisswenger PJ; Howell SK; O'Dell RM; Wood ME; Touchette AD; Szwergold BS
    Diabetes Care; 2001 Apr; 24(4):726-32. PubMed ID: 11315838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects on post-prandial glucose and AGE precursors from two initial insulin strategies in patients with type 2 diabetes uncontrolled by oral agents.
    Sakharova OV; Lleva RR; Dziura JD; Spollett GR; Howell SK; Beisswenger PJ; Inzucchi SE
    J Diabetes Complications; 2012; 26(4):333-8. PubMed ID: 22541894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes.
    Ahmed N; Babaei-Jadidi R; Howell SK; Beisswenger PJ; Thornalley PJ
    Diabetologia; 2005 Aug; 48(8):1590-603. PubMed ID: 15988580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining the role of insulin lispro in the management of postprandial hyperglycaemia in patients with type 2 diabetes mellitus.
    Giugliano D; Ceriello A; Razzoli E; Esposito K
    Clin Drug Investig; 2008; 28(4):199-210. PubMed ID: 18345710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nepsilon-(carboxymethyl) lysine independently of glycohaemoglobin concentrations.
    Hammes HP; Brownlee M; Lin J; Schleicher E; Bretzel RG
    Diabetologia; 1999 May; 42(5):603-7. PubMed ID: 10333054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime.
    Ciofetta M; Lalli C; Del Sindaco P; Torlone E; Pampanelli S; Mauro L; Chiara DL; Brunetti P; Bolli GB
    Diabetes Care; 1999 May; 22(5):795-800. PubMed ID: 10332684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal administration of lispro insulin in hyperglycemic type 1 diabetes.
    Rassam AG; Zeise TM; Burge MR; Schade DS
    Diabetes Care; 1999 Jan; 22(1):133-6. PubMed ID: 10333914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group.
    Anderson JH; Brunelle RL; Koivisto VA; Pfützner A; Trautmann ME; Vignati L; DiMarchi R
    Diabetes; 1997 Feb; 46(2):265-70. PubMed ID: 9000704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes.
    Pfützner A; Küstner E; Forst T; Schulze-Schleppinghoff B; Trautmann ME; Haslbeck M; Schatz H; Beyer J
    Exp Clin Endocrinol Diabetes; 1996; 104(1):25-30. PubMed ID: 8750567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group.
    Roach P; Trautmann M; Arora V; Sun B; Anderson JH
    Clin Ther; 1999 Mar; 21(3):523-34. PubMed ID: 10321421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy.
    Kazda C; Hülstrunk H; Helsberg K; Langer F; Forst T; Hanefeld M
    J Diabetes Complications; 2006; 20(3):145-52. PubMed ID: 16632233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.
    Feinglos MN; Thacker CH; English J; Bethel MA; Lane JD
    Diabetes Care; 1997 Oct; 20(10):1539-42. PubMed ID: 9314631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
    Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
    Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.
    Anderson JH; Brunelle RL; Keohane P; Koivisto VA; Trautmann ME; Vignati L; DiMarchi R
    Arch Intern Med; 1997 Jun; 157(11):1249-55. PubMed ID: 9183237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin.
    Ebeling P; Jansson PA; Smith U; Lalli C; Bolli GB; Koivisto VA
    Diabetes Care; 1997 Aug; 20(8):1287-9. PubMed ID: 9250455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced glycation endproducts, dityrosine and arginine transporter dysfunction in autism - a source of biomarkers for clinical diagnosis.
    Anwar A; Abruzzo PM; Pasha S; Rajpoot K; Bolotta A; Ghezzo A; Marini M; Posar A; Visconti P; Thornalley PJ; Rabbani N
    Mol Autism; 2018; 9():3. PubMed ID: 29479405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents.
    Holcombe JH; Zalani S; Arora VK; Mast CJ;
    Clin Ther; 2002 Apr; 24(4):629-38. PubMed ID: 12017407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic efficacy of preprandial administration of Lys(B28), Pro(B29) human insulin analog in IDDM patients. A comparison with human regular insulin during a three-meal test period.
    Jacobs MA; Keulen ET; Kanc K; Casteleijn S; Scheffer P; Devillé W; Heine RJ
    Diabetes Care; 1997 Aug; 20(8):1279-86. PubMed ID: 9250454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.
    Ahmed AB; Home PD
    Diabetes Care; 1998 Jan; 21(1):32-7. PubMed ID: 9538967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.